This multi-center retrospective pilot study evaluated the current state of HF medication therapy in children and found that, despite a robust evidence base in adults and recommendations for children, use of ACEi/ARB/ARNi, BB, and MRA is not universal in children with EF <40%; indeed, less than half of children received medications from all three classes by 6 months of follow-up...
The ACTION VADs score for mortality can be calculated easily and offers risk stratification and prognostic information for pediatric VAD candidates. This is the first validated risk assessment tool for pediatric mechanical circulatory support.
ACTION gives this three year old HeartMate 3™ LVAD Patient Education Handbook an update!
HeartMate 3™ LVAD Patient Education Handbook – UPDATED! Read More »
Happy Fall to All! We had a successful meeting during the Single Ventricle Investigators Meeting in Denver this month, and it was great to see so many of you in person! Many new junior faculty and leaders of all experience levels have joined ACTION, and we are excited to continue our progress in the VAD, Heart Failure, Muscular Dystrophy, and Fontan spaces. We are grateful for the engagement and collaboration from all stakeholders that continue to excel our research, quality improvement, education, and advocacy efforts.
The Pulse — November 2024 Read More »
ACTION and the Academic Research Consortium (ARC) aimed to harmonize definitions of pediatric and CHD AEs for use in clinical trials, registries, and regulatory evaluation.
Poster Session 5:40 –7:00 PM PST | Friday, November 15th Impact of LVAD Support with Impella 5.5 to Bridge Adolescents to Heart Transplant – An Evolving Strategy Cihangir Buyukgoz,
Poster Session 5:40 –7:00 PM | Saturday, November 16th Oxygenator use in Ventricular Assist Devices from the Advanced Cardiac Therapies Improving Outcomes Network (ACTION) Registry Rabinowitz, Edon, et al.
ACTION and the Academic Research Consortium (ARC) aimed to harmonize definitions of pediatric and CHD AEs for use in clinical trials, registries, and regulatory evaluation.
ACTION is excited to release our first patient and family education handbook focused on Heart Failure Success!
NEW! Heart Failure Success Patient & Family Education Handbook Read More »
What: Poster Session When: Friday, October 11 from 2:15-3:15 pm Dystrophinopathy in ACTION; Analysis of the first 500 males enrolled in the Advanced Cardiac Therapies Improving Outcomes Network prospective
29th Annual Congress of World Muscle Society- ACTION Abstracts Poster Session Read More »
